Bioassays demonstrated potent dose-dependent anti-inflammatory activity through NF-κB suppression, alongside selective cytotoxicity against HepG2 hepatocellular carcinoma cells, indicating therapeutic potential in inflammation-associated cancers. This evidence concerns the gene NFKB1 and hepatocellular carcinoma.